Hampel, Paul J. http://orcid.org/0000-0003-1292-3024
Rabe, Kari G. http://orcid.org/0000-0002-7313-1875
Call, Timothy G.
Ding, Wei http://orcid.org/0000-0001-9811-4601
Leis, Jose F.
Chanan-Khan, Asher A.
Kenderian, Saad S. http://orcid.org/0000-0003-2767-3830
Muchtar, Eli http://orcid.org/0000-0003-2210-2174
Wang, Yucai http://orcid.org/0000-0002-1576-8341
Ailawadhi, Sikander http://orcid.org/0000-0002-8377-8111
Koehler, Amber B.
Parrondo, Ricardo
Schwager, Susan M.
Sher, Taimur
Hanson, Curtis A.
Shi, Min http://orcid.org/0000-0002-5741-4293
Van Dyke, Daniel L.
Braggio, Esteban
Slager, Susan L. http://orcid.org/0000-0002-5173-4712
Kay, Neil E. http://orcid.org/0000-0002-5951-5055
Parikh, Sameer A. http://orcid.org/0000-0002-3221-7314
Article History
Received: 1 July 2022
Revised: 11 August 2022
Accepted: 12 August 2022
First Online: 1 September 2022
Competing interests
: The authors declare no competing financial interests in direct relation to the work reported. The following authors also declare no competing financial interests otherwise: PJH, KGR, TGC, JFL, RP, SMS, TS, CAH, MS, DLVD, EB, SLS,. In the interest of transparency, additional potential conflicts of interest for the remaining authors are included subsequently. WD: Research funding has been provided to the institution from Merck and DTRM. Participation in advisory board meetings for Merck and Octapharma. AAC-K: Consultancy for BieGene, Janssen, and Ascentage. Equity holder in Cellectar. Stock options in Alpha2 Pharmaceuticals, NonoDev, Starton. Research funding from Ascentage. Patents and royalties in Alpha2 Pharmaceuticals. Membership on Board of Directors or advisory committees for Acentage, Starton, Cellectar, NonoDev, and Alpha2 Pharmaceuticals. Honoraria from BeiGene, Janssen, Acentage. SSK: Consultancy, honoraria, and research funding from Humanigen, Inc. EM: Honorarium from Janssen. Consultation fee from Protego (paid to the institution). YW: Membership on Board of Directors or advisory committies for Incyte, LOXO Oncology, Eli Lilly, TG Therapeutics. Research funding from Incyte, InnoCare, LOXO Oncology, Novartis, Genentech, MorphoSys. SA: Consultancy for BMS, Janssen, Amgen, Pharmacyclics, GSK, Takeda, Genentech, AbbVie, Karyopharm, Beigene, Sanofi. Research funding from BMS, Janssen, Amgen, Pharmacyclics, Ascentage, Medimmune, Cellectar, Xencor, GSK. ABK: Membership on Board of Directors or advisory committees for AbbVie and TG Therapeutics. NEK: Membership on Board of Directors or advisory committees for Abbvie, BMS, Celgene, Pharmacyclics, AstraZeneca, Behring, CytomX Therapeutics, Dava Oncology, Janssen, Juno Therapeutics, Oncotracker, Targeted Oncology, Agios Pharm, MorphoSys, Rigel. Research funding from Abbvie, Acerta Pharma, BMS, Celgene, Genentech, MEI Pharma, Sunesis, TG Therapeutics, Tolero Pharmaceuticals. SAP: Research funding has been provided to the institution from Pharmacyclics, Janssen, AstraZeneca, TG Therapeutics, Merck, AbbVie, and Ascentage Pharma for clinical studies in which SAP is a principal investigator. SAP has received honoraria for participation in consulting activities/advisory board meetings for Pharmacyclics, Merck, AstraZeneca, Genentech, GlaxoSmithKline, Adaptive Biotechnologies, Amgen, and AbbVie (no personal compensation); and from DynaMed, Aptitude Health, Curio Science, and MedEd on the Go (with personal compensation).